Lecturer in Law
Kamil Ali-Jackson is the co-founder and former Chief Legal Officer, Chief Compliance Officer, and Secretary of the Board of Aclaris Therapeutics, Inc., a NASDAQ-listed biopharmaceutical company.
Ali-Jackson’s career spans more than 35 years of experience as a serial entrepreneur and attorney in emerging, mid-size, and large life sciences companies. She is a C-suite leader and business partner with extensive legal, mergers and acquisitions, business development, product licensing, corporate governance, compliance, and human resources experience.
She has co-founded several specialty pharmaceutical and biopharmaceutical companies and successfully transitioned those companies through multi-million-dollar acquisitions by global pharmaceutical companies.
Ali-Jackson currently serves on the board of directors of two NASDAQ-listed companies: Rigel Pharmaceuticals, Inc., a commercial stage biotechnology company with a hematologic disorders, oncology, and rare immune disease therapeutic focus, and PDS Biotechnology Corporation, a clinical stage biopharmaceutical company developing cancer immunotherapies and infectious disease vaccines.
She also serves on the boards of privately held companies and nonprofit organizations, is an inaugural member of the Princeton University Dean for Research External Advisory Council for Innovation and Entrepreneurship, and Lecturer in Law at the University of Pennsylvania Carey Law School.
Ali-Jackson received a Juris Doctorate from Harvard Law and a Bachelor of Arts in politics from Princeton. She is married to an attorney and is the mother of four children.